- Home
- EDRY vs GDTC Comparison
EDRY vs GDTC Comparison
Compare EDRY & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- GDTC
- Stock Information
- Founded
- EDRY 2018
- GDTC 2018
- Country
- EDRY Greece
- GDTC Singapore
- Employees
- EDRY N/A
- GDTC N/A
- Industry
- EDRY Marine Transportation
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- GDTC Health Care
- Exchange
- EDRY Nasdaq
- GDTC Nasdaq
- Market Cap
- EDRY 31.7M
- GDTC 29.4M
- IPO Year
- EDRY N/A
- GDTC 2023
- Fundamental
- Price
- EDRY $10.83
- GDTC $2.65
- Analyst Decision
- EDRY
- GDTC Buy
- Analyst Count
- EDRY 0
- GDTC 1
- Target Price
- EDRY N/A
- GDTC $5.00
- AVG Volume (30 Days)
- EDRY 8.1K
- GDTC 33.6K
- Earning Date
- EDRY 02-18-2025
- GDTC 01-01-0001
- Dividend Yield
- EDRY N/A
- GDTC N/A
- EPS Growth
- EDRY N/A
- GDTC N/A
- EPS
- EDRY N/A
- GDTC N/A
- Revenue
- EDRY $65,085,280.00
- GDTC $330,254.00
- Revenue This Year
- EDRY $34.61
- GDTC $14.71
- Revenue Next Year
- EDRY $15.93
- GDTC N/A
- P/E Ratio
- EDRY N/A
- GDTC N/A
- Revenue Growth
- EDRY 39.04
- GDTC N/A
- 52 Week Low
- EDRY $10.04
- GDTC $1.20
- 52 Week High
- EDRY $24.84
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- EDRY 41.74
- GDTC 55.89
- Support Level
- EDRY $10.40
- GDTC $2.35
- Resistance Level
- EDRY $11.18
- GDTC $2.94
- Average True Range (ATR)
- EDRY 0.49
- GDTC 0.24
- MACD
- EDRY 0.00
- GDTC 0.04
- Stochastic Oscillator
- EDRY 30.71
- GDTC 84.63
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulks such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.